Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Orgenesis Inc (ORGS)

Orgenesis Inc (ORGS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Orgenesis Inc 20271 Goldenrod Lane Germantown MD 20876 USA

P: 480-659-6404

Description:

Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.

Key Statistics

Overview:

Market Capitalization, $K 70,295
Shares Outstanding, K 15,621
Annual Sales, $ 18,660 K
Annual Net Income, $ -18,290 K
Last Quarter Sales, $ 7,300 K
Last Quarter Net Income, $ -8,310 K
60-Month Beta 0.72
% of Insider Shareholders 8.07%
% of Institutional Shareholders 4.27%
Float, K 14,360
% Float 91.93%

Growth:

1-Year Return -51.15%
3-Year Return -1.32%
5-Year Return -6.25%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 07/16/19
Earnings Per Share ttm -0.74
EPS Growth vs. Prev Qtr -11.43%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-12 on 11/16/17

ORGS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -10.86
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -106.36
Return-on-Assets (Before Tax) -34.32
Profit Margin % -98.02
Net Margin % N/A
Debt/Equity 0.16
Price/Sales 3.44
Price/Cash Flow N/A
Price/Book 3.00
Book Value/Share 1.37
Interest Coverage -4.70
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar